Clicky

Akeso Inc(9926) News

Date Title
Aug 14 Asian Growth Companies With High Insider Ownership In August 2025
Aug 11 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11 Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
Aug 4 Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
Jul 31 Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
Jul 28 Could bispecifics unseat Keytruda from its oncology throne?
Jul 28 NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
Jul 24 Exploring Three High Growth Tech Stocks In Asia
Jul 24 Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
Jul 16 3 Asian Growth Companies With High Insider Ownership And 58% Earnings Growth
Jul 16 Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%
Jul 16 Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
Jul 13 China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
Jul 10 Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
Jul 10 Agile Occupational Medicine and Akeso Occupational Health Merge to Form Leading West Coast Occupational Health Platform
Jul 9 Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
Jun 25 High Growth Tech Stocks in Asia for June 2025
Jun 16 Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
May 19 Asian Growth Companies With High Insider Ownership
May 19 Global Value Stocks: 3 Companies That May Be Priced Below Their Intrinsic Estimates